HER2-Mutant NSCLC: Closing the Gap Between Detection and Optimal Treatment Assessment

What you'll learn

Course overview

Non small lung cancer (NSCLC) is a biologically diverse type of lung cancer driven by a wide array of molecular alterations. Human epidermal growth factor receptor 2 (HER2) alterations occur in approximately 4% of patients with NSCLC and include gene mutations, gene amplifications, and protein overexpression. HER2-targeted therapies, including antibody-drug conjugates and tyrosine kinase inhibitors, have shown promising efficacy for patients with limited treatment options. Testing for HER2 alterations is crucial in order to identify patients who may benefit from targeted therapies, and interprofessional collaboration is critical to optimizing timely diagnosis and personalized management throughout the care continuum (Ismail et al, 2025). In this activity, Maria E. Arcila, MD, Attending Physician and Deputy Chief of the Molecular Diagnostics Service in the Department of Pathology and Laboratory Medicine at Memorial Sloan Kettering Cancer Center, and Helena A. Yu, MD, Attending Physician and Thoracic Medical Oncologist at Memorial Sloan Kettering Cancer Center, will explore strategies for closing the gap between detection and optimal treatment in NSCLC with HER2 alterations.